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Abstract 
Background: Elevation of soluble suppression of tumorigenicity 2 (sST2) is associated with 
cardiac fibrosis and hypertrophy. Under investigation herein, was whether sST2 level is 
associated with major adverse cardiac events (MACE) and left ventricular (LV) remodeling 
after primary percutaneous coronary intervention (PCI) in patients with acute ST-segment 
elevation myocardial infarction (STEMI). 
Methods: In total, this study included 184 patients who underwent successful primary PCI.  
A subsequent guideline-based medical follow-up was included (61.4  11.8 years old, 85% 
male, 21% with Killip class ≥ Ⅰ). sST2 concentration correlations with echocardiographic, 
angiographic, laboratory parameters, and clinical outcomes in STEMI patients were 
evaluated.  
Results: The median sST2 level was 60.3 ng/mL; 6 (3.2%) deaths occurred within 1 year. 
The sST2 level correlated with LV ejection fraction (EF) changes from baseline to 6 months 
(r= –0.273; p = 0.006) after adjustment for echocardiographic parameters including wall 
motions score index (WMSI). Recovery of LVEF at 6 months was highest in the tertile 1 
group (∆6 months – baseline LVEF; tertile 1, p = 0.001; tertile 2, p = 0.319; tertile 3, p = 
0.205). The decrease in WMSI at 6 months was greater in the tertiles 1 and 2 groups than in 
the tertile 3 group (∆6 months – baseline WMSI; tertile 1, p = 0.001; tertile 2, p = 0.013; 
tertile 3, p = 0.055). There was no association between sST2 levels and short-term (log lank p 
= 0.598) and long-term (p = 0.596) MACE. 
Conclusions: sST2 concentration have predictive value for LV remodeling on 
echocardiography in patients with STEMI who underwent primary PCI. However, sST2 
concentration was not associated with short-term and long-term MACE.  
Key words: suppression of tumorigenicity 2 protein, myocardial infarction, left 
ventricular remodeling 
 
 
Introduction 
Acute ST-segment elevation myocardial infarction (STEMI) makes a significant 
contribution to morbidity and mortality in many parts of the world [1–4]. It is well known 
that early diagnosis and proper management, especially delay from the onset of symptoms to 
revascularization are important for long-term prognosis [5, 6]. Timely diagnosis allows 
physicians to stratify their patients by risk, and consequently provides them with the 
opportunity to select appropriate treatments. Biomarkers have been used to assist with timely 
diagnosis and to predict precise short- or long-term prognosis in STEMI patients. As a result, 
cardiac biomarkers, such as creatine phosphokinase (CPK), creatinine kinase-myocardial 
band (CK-MB), cardiac specific troponins, and natriuretic peptides, are widely used to 
diagnose and predict prognosis in patients with STEMI [7–9]. Circulating soluble suppression 
of tumorigenicity 2 (sST2) is a known biomarker of cardiac remodeling and inflammation, 
especially in heart failure (HF) patients. It is thought to act as a decoy receptor for 
interleukin-33, rendering it unavailable to membrane-bound ST2 receptors that medicate anti-
inflammatory and anti-fibrotic effects [10–12]. Several studies have reported that increased 
sST2 in the initial phase of STEMI is closely related to adverse outcomes, both in the short- 
and long-term [13–16]. However, current guidelines do not recommend the examination of 
sST2 as a biomarker in the treatment for STEMI. Therefore, under investigation herein, are 
the associations between the concentration of sST2 and the clinical and echocardiographic 
outcome.Its performance was compared to established risk predictors such as the Killip 
classification, Thrombolysis in Myocardial Infarction (TIMI) risk score, and the Canadian 
acute coronary syndrome (CACS) score.  
 Methods 
Study design and population 
The study was a single center, retrospective, observational study. The study 
population consisted of 184 patients who underwent successful primary percutaneous 
coronary intervention (PCI) for STEMI from January 2014 to April 2017 at the Chungbuk 
National University Hospital, Republic of Korea. In total, 184 patients were included. Figure 
1 shows the study flow chart. Written informed consent was obtained from all patients, and 
exclusion criteria were as follows: (1) end-stage renal disease requiring dialysis; (2) life 
expectancy < 12 months; (3) pre-hospital or pre-PCI cardiac arrest (4) prior coronary artery 
bypass graft surgery; (5) known malignancy or inflammatory disease. The study complied 
with the Declaration of Helsinki and was approved by the institutional review board (IRB) of 
Chungbuk National University Hospital (CBNUH 2018-07-013). 
 
Laboratory assays 
All plasma samples were collected before primary PCI with arterial access. The 
plasma samples were stored in plastic cryovials at –80℃ at the Chungnbuk National 
University Hospital Brach Bank of the Korean Biobank Network until required for analysis. 
The sST2 concentration in blood specimens was measured using an enzyme-linked 
immunosorbent assay kit (ELISA) (Elabscience Biotechnology, China) [17]; calibration and 
standardization were performed according to the manufacturer instructions. Intra-assay and 
inter-assay coefficients of variance were reported as < 2.5% and < 4.0%, respectively [18]. To 
examine a dose-response relationship between sST2 and outcomes, tertiles of sST2 were 
analyzed and defined as tertile 1: 0 < 53.6 ng/mL, tertile 2: 53.6 ≤ sST2 < 72.0 (ng/mL), and 
tertile 3: sST2 ≥ 72.0 (ng/mL). 
 
Initial treatment strategies 
The initial treatments in hospitalized patients with STEMI were administration of 
loading doses for dual antiplatelet agents (DAPT) and primary PCI that was performed after 
intravenous administration of 7,000 IU of heparin. Second generation drug-eluting stents 
were implanted in all patients, and the decision on whether to use intravascular imaging 
modalities, an intra-aortic balloon pump, thrombectomy devices, or extracorporeal membrane 
oxygenation devices was made by the operator.  
Time for revascularization was determined in three ways: (1) time from symptom 
onset to balloon inflation, (2) time from symptom onset to medical contact, and (3) time from 
medical contact to balloon inflation. All patients received standard medical treatment with 
revascularization at the discretion of the attending physician. 
 
Echocardiographic measurement 
All patients underwent transthoracic echocardiography (IE33, Philips Medical 
System, Andover, MA, USA; Vivid 7, GE Vingmed Ultrasound, Horten, Norway; SC2000, 
Siemens, Erlangen, Germany) within 12 hours of the index procedure. The left ventricular 
(LV) systolic function (LV ejection fraction [LVEF]), LV internal dimension at diastole 
(LVIDd), ratio of the early diastolic peak mitral inflow velocity to early diastolic mitral 
annular velocity (E/E’), left atrial volume index (LAVI), and wall motion score index 
(WMSI) were obtained according to the American Society of Echocardiography guidelines 
[19]. Follow-up echocardiography was performed 6 months after discharge at outpatient 
clinics. ∆LVEF, ∆LVIDd, ∆E/E’, ∆LAVI, and ∆WMSI were defined by subtracting the 
baseline echocardiographic parameters from the echocardiographic performed 6 months after 
discharge from initial hospitalization. 
 
Follow-up and endpoint 
Standard medications, including DAPT, beta blockers, renin–angiotensin–
aldosterone system inhibitors, statins, and nitrates, were provided by responsible physicians 
according to the guidelines. The primary endpoint was major adverse cardiac event (MACE) 
at 1 year; this comprised of occurrence of cardiovascular death, non-fatal MI, and non-fatal 
stroke. The secondary endpoint was differences in echocardiographic parameters indicating 
LV remodeling between baseline and 6-month follow-up. The endpoints were obtained by 
reviewing electronic hospital medical records.  
 
Statistical analysis 
Demographic, clinical, echocardiographic, and laboratory variables were described 
as means and standard deviation (SD) in normally distributed variables, and variables with a 
non-normal distribution were described as medians and interquartile range (IQR). The 
analysis of variance was used to compare normally distributed variables, and the Kruskal-
Wallis test was used to compare continuous variables in a state of non-normality. Categorical 
variables were compared using the χ2 test or the Fisher exact test. Univariable Pearson and 
Spearman correlation and partial correlation were used to evaluate the magnitude and 
significance of relationships among continuous variables. 
The Wilcoxon signed rank test was used to compare changes in echocardiographic 
parameters by time within groups. Multiple Cox proportional hazard analyses were 
performed in an effort to identify independent predictors of 1-year MACE after primary PCI. 
Variables were retained and entered into a multivariable model if their univariable p value 
was < 0.05. 
The Kaplan-Meier method was used to estimate event-free survival, and differences 
between the curves were compared using the log-rank test. 
Analyses were performed using SPSS 25.0 (SPSS Inc, Chicago, IL, USA), and SAS 
9.4 (SAS Institute Inc, Cary, NC, USA). P-values (two-tailed) < 0.05 were considered to 
indicate statistical significance. 
 
Results 
Patient characteristics related to sST2 tertile 
In total, 184 subjects, who were followed up 1 year after successful primary PCI for 
STEMI, were evaluated in this study. The mean age of the subjects was 61.4 ± 11.8 years, and 
15% were female. In addition, 57% had a culprit lesion in the left anterior descending artery 
(LAD), the median (IQR) symptom to door time was 120 (53, 267) min, the door to balloon 
time was 39 (30, 50) min, 21% were Killip classification ≥ 2, 54% were TIMI risk score > 4, 
17% were CACS score > 1, and 100% presented with STEMI. The median sST2 
concentration was 60.3 ng/mL (25th, 75th percentile: 48.7, 77.3 ng/mL, respectively; range: 
23.2–197.5 ng/mL). Of these, 62 patients (33.6%) were included in tertile 1, 61 (33.2%) 
patients were included in tertile 2, and 61 (33.2%) patients were included in tertile 3. The 
baseline characteristics of patients stratified by sST2 concentration are shown in Table 1. 
Higher sST2 concentration showed an association with trends for old age, hypertension, 
higher Killip classification, TIMI risk score, and CACS score, although these were not 
statistically significant. Furthermore, the sST2 level was not associated with age, body 
weight, sex, smoking, prior angina, diabetes, culprit lesion, and time from symptom onset to 
initiation of primary PCI. The levels of initial and peak CPK, CK-MB, and cardiac specific 
troponin were not significantly higher in the higher sST2 tertile groups compared to tertile 1. 
Inflammatory biomarkers, including high sensitivity C-reactive protein (hs-CRP), white 
blood cell (WBC) and eosinophil count, were not significantly different among three groups 
of sST2 concentration. There were no differences in the short- and long-term MACEs based 
on sST2 concentration. 
 sST2 and echocardiographic angiographic data 
A summary of the echocardiographic data is provided in Tables 2 and 3. When 
categorized by sST2 concentration, there were no significant differences in the baseline and 
follow-up in terms of LVEF, LVIDd, E/E’, LAVI, and WMSI among the sST2 tertile groups 
(Table 2). However, in terms of changes in echocardiographic parameters, a lower sST2 
concentration was associated with ∆LVEF (absolute percent point difference of LVEF at 6 
month vs. baseline; tertile 1, 7.3 [–0.8, 15.8], p = 0.001; tertile 2, 1.3 [–4.3, 9.1], p = 0.319; 
tertile 3, 1.7 [–8.1, 10.1], p = 0.205) and ∆WMSI (absolute numeric difference of WMSI at 6 
month vs. baseline; tertile 1, –0.1 [–0.2, 0], p = 0.001; tertile 2, –0.1 [–0.2, 0.1], p = 0.013; 
tertile 3, 0 [–0.3, 0], p = 0.055; Table 3 and Fig. 2).  
 
sST2 levels in relation to other biomarkers and risk stratification strategies 
A significant univariate association was found only between baseline sST2 
concentration and ∆LVEF (r = –0.232, p = 0.018). The baseline troponin-T level was not 
statistically significant but showed a correlation tendency with baseline sST2 concentration (r 
= 0.144, p = 0.051). Following adjustment for the relevant variables, partial correlation 
analysis showed a constant association between sST2 concentration and ∆LVEF (r = –0.273, 
p = 0.006; adjusted by ∆LVIDd, ∆E/E’, ∆LAVI, and ∆WMSI). 
According to categories in the known risk stratification strategies, including Killip 
classification, TIMI risk score, and CACS score, there were no significant differences 
between risk scores (Fig. 3). In the linear regression model, no significant associations were 
found between sST2 and known risk stratification strategies (sST2 and Killip classification, β 
= 0.005, p = 0.320; sST2 and TIMI risk score, β = 0.008, p = 0.220; sST2 and CACS score, β 
= 0.008, p = 0.222). However, there were significant associations among risk stratification 
strategies (TIMI risk score and Killip classification, β = 0.382, p < 0.001; CCAS score and 
Killip classification, β = 0.605, p < 0.001; TIMI risk score and CACS score, β = 0.658, p < 
0.001).  
 
Association between adverse outcomes and sST2 concentration 
Over the course of 1 year following the index PCI, 6 MACE occurred (6 
cardiovascular deaths), with an event rate of 3%, and all events occurred within 30 days. Cox 
regression analysis was used to identify independent predictors for MACE after primary PCI, 
and the results are shown in Table 4. Baseline systolic blood pressure, symptom to door time, 
symptom to balloon time, TIMI risk score, and CACS score were independently associated 
with 1-year MACE by univariate analysis. After adjusting these variables, baseline systolic 
blood pressure (HR 0.97 [0.94–0.99], p = 0.011) was found to independently predict 1-year 
MACE in this registry. sST2 concentration was not shown to be associated with both short- 
and long-term outcomes by survival analysis (Fig. 4).  
 
Discussion 
Main findings 
The current study sought to explore the relationship among pre-procedural serum 
sST2 concentration and clinical, echocardiographic, and laboratory results in patients with 
STEMI. The results demonstrated that an elevated concentration of sST2 was a negative 
predictor of improvement in LV systolic function 6 months after index primary PCI and lower 
sST2 tertile groups were associated with a significant improvement in WMSI at 6 months. 
However, a higher sST2 level was not shown to be a predictor of adverse cardiovascular 
outcomes, independent of traditional risk stratification strategies, including the TIMI risk 
score, Killip classification, and CACS score for STEMI. Furthermore, the sST2 level was not 
associated with other biomarkers, including peak CPK, CK-MB, and cardiac specific 
troponin, and was not shown to be associated with other risk stratification strategies. The 
location of culprit lesions was not associated with serum sST2 concentration. there was no 
statistical association found between the serum sST2 concentration and adverse 
cardiovascular outcomes after primary PCI in this single registry. 
 
sST2 and cardiovascular disease 
It is known that ST2, an IL-1 receptor (IL-1R) family member, is basally expressed 
by cardiomyocytes [20]. ST2 consists of membrane and soluble forms, and an increase in 
soluble ST2 has been shown to negatively impact the cardioprotective effect, which in turn, 
can lead to myocardial remodeling and fibrosis [21, 22]. This finding raised the possibility 
that the concentration of sST2 may be of predictive value in cardiovascular disease. Indeed, 
preclinical studies have shown upregulation of sST2 in cardiomyocytes in models of 
myocardial infarction [23], while clinical studies have demonstrated the association between 
a higher sST2 concentration and adverse cardiovascular outcomes in patients with STEMI 
[13–16, 24]. Furthermore, several studies have demonstrated that short-term changes in sST2 
concentration were prognostic of mortality in severe HF [25] among dyspneic patients with 
and without acute HF [26]. Many further reports corroborated the prognostic power of sST2 
in multiple acute and chronic cardiovascular settings [27, 28]. 
 
sST2 as a predictor of 30-day and 1-year MACE after primary PCI 
Two reports on data derived from three randomized clinical trials in patients with STEMI 
provide data on the predictive value of serum sST2 concentration for adverse outcome up to 
30-days after MI, while further studies reported on prognostic implications up to a median 
follow-up period of 20 months [13, 29, 30]. Shimpo et al. [29] showed that an ascending 
quartile of serum sST2 concentration significantly corresponded to increasing time from 
symptom onset, higher heart rates, higher cardiac troponin-I, higher B-type natriuretic peptide 
(BNP), higher CRP, higher creatinine, and an increasing likelihood of an anterior location of 
the MI. However, in the present study, the sST2 level was not correlated with other 
biomarkers, culprit lesion of MI, and time from symptom onset to door/balloon. Sabatine et 
al. [13] revealed that sST2 and NT-proBNP were found to have complementary roles in 
STEMI compared to the TIMI risk score. Dhillon et al. [30] also demonstrated a correlation 
between sST2 and the Global Registry of Acute Coronary Events (GRACE) risk score. 
However, in the current study, the proBNP level was collected in only 19 subjects and  
performing a correlation analysis between sST2 and proBNP was not possible. Furthermore, 
sST2 concentration was not associated with risk stratification strategies including TIMI risk 
score, Killip classification, and CACS score.  
Although a small number of subjects have been included, contrary to prior studies in 
STEMI [13, 15, 16], the present results did not provide a prognostic power of serum sST2 
concentration for adverse cardiovascular outcomes. One possible argument for this 
discrepancy is that restoration time of flow from symptoms onset affect to myocardial 
damage which is related to increased biomechanical strain that causes higher sST2 levels. 
Severe myocardial damage and remodeling is expected in a relatively long term from 
symptom onset. Previous studies have revealed the time from symptom onset to lytic therapy 
2.4 ± 1.3 h to 4.2 ± 3.0 h [13], and 2.8 ± 1.6 to 4.0 ± 1.9 [29]. Analysis of serial 
measurements of serum sST2 in 228 patients showed an increase sST2 with time especially 
after 3 h, with a peak level at 12 h for most patients [29]. It was identified herein, that the 
time from symptom to PCI (median; 2.7–2.8 h) was revealed to be relatively less than in 
previous studies. This indicates that, perhaps the impact of serum sST2 level would not have 
been strong in this study. 
 
sST2 and LV remodeling 
While data related to circulating sST2 concentration to cardiac function and structure 
are variable and sparse, some reports have shown a weak inverse relationship between sST2 
level and various cardiovascular disease cohorts [31]. Weir et al. [32] analyzed the 
relationship between sST2 and serial change in LV function after acute MI measured by 
cardiac magnetic resonance imaging, NT-proBNP, norepinephrine, and aldosterone at 
baseline and at 12- and 24-week follow-up. It was demonstrated that sST2 had a significant 
inverse correlation with the change in LVEF between baseline and 6-month follow-up. In 
addition, the LV end-diastolic volume index was correlated with changes in sST2 
concentration.  An inverse correlation was demonstrated between the serial change in LVEF, 
WMSI by transthoracic echocardiography, and baseline sST2 tertile. Furthermore, the LVEF 
was significantly increased after 6 months in tertile 1, and WMSI was significantly improved 
after 6 months in tertiles 1 and 2. The serum sST2 concentration after STEMI was related to 
mid-term changes in LV function and remodeling.  
 
Limitations of the study 
The present study should be interpreted in the context of its limitations. First, the 
present study is observational and was a relatively small single-center retrospective study. 
The treatment groups may have been confounded by selection bias. Nevertheless, the cohort 
registry was homogenous, and all study populations included STEMI patients who underwent 
primary PCI and were managed using the same protocol. Secondly, the blood for sST2 
measurements was taken at the presentation of STEMI, and the follow-up sST2 values were 
not examined. Third, 93%, 86%, and 81% of patients not 100% took statin, beta-blocker, and 
angiotensin converting enzyme inhibitor (ACEI) or angiotensin Ⅱ receptor blocker (ARB) 
during in-hospital day due to elevated liver enzyme in the case of statin, marked sinus 
bradycardia even if there were no symptoms in the case of beta-blocker, and suspected acute 
kidney injury or electrolyte imbalance, such as hyperkalemia in the case of ACEI or ARB. 
However, most of these drugs were administered unless there was a specific contraindication 
during outpatient clinic term. Fourth, the time from the first symptom onset to hospital or PCI 
was quite short compared to that of the Korea Acute Myocardial Infarction Registry 
(KAMIR), which is the nationwide, prospective, multicenter registry of Korean patients with 
acute MI (symptom onset to balloon time; median 220 min at 2014; 210 min at 2015; 200 
min at 2016; and 212 min at 2017) [3]. Differences were found, including short-and long-
term MACE, in this registry compared to the KAMIR data. Although it is considered possible 
that a relatively short reperfusion time from symptom onset may have affected the outcome, 
this could not be determined in this study. 
Finally, most previous studies of sST2 in cardiac disease applied different assays than 
those used in the current study; this limits the transferability of the present results to findings 
of previous investigations. 
 
Conclusions 
In conclusion, lower values of sST2, obtained at the time of presentation at hospital 
in patients with STEMI resulted in less damaged myocardium and improved LV systolic 
function in the mid-term which is associated with a lesser likelihood of LV remodeling. 
However, higher values of sST2 were not associated with either short- or long-term MACE. 
Data herein, provides valuable information on clinical outcomes and the structural association 
with sST2 concentration.  
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Table 1. Baseline characteristics according to sST2 tertile in patients with ST-elevated myocardial infarction. 
Variables 
 sST2 [ng/mL] 
Overall (n = 184) 
Tertile 1 
23.2 ≤ sST2 < 53.6 
 (n = 62) 
Tertile 2 
53.6 ≤ sST2 < 72.0 
(n = 61) 
Tertile 3 
72.0 ≤ sST2   
(n = 61) 
P 
Age [years] 61.4 ± 11.8 58.4 ± 9.8 63.0 ± 12.7 62.5 ± 12.3 0.058 
Body weight [kg] 67.8 ± 12.4  68.8 ± 11.8 66.6 ± 13.0 68.5 ± 12.2 0.554 
Female 28 (15%) 9 (15%) 8 (13%) 11 (18%) 0.763 
Baseline HR [bpm] 76 ± 20 75 ± 20 76 ± 18 77 ± 22 0.910 
Baseline SBP [mmHg] 130 (110, 145) 130 (110, 149) 130 (110, 140) 130 (109, 146) 0.885 
Baseline DBP [mmHg] 80 (70, 90) 80 (70, 90) 79 (70, 90) 80 (70, 90) 0.597 
Symptom to door time [min] 120 (53, 267) 117 (40, 280) 120 (58, 201) 120 (49, 342) 0.876 
Symptom to balloon time [min] 160 (88, 300) 162 (87, 315) 168 (87, 248) 160 (93, 380) 0.911 
Door to balloon time [min] 39 (30, 50) 40 (30, 52) 37 (28, 50) 40 (33, 50) 0.343 
Prior angina 8 (4%) 3 (5%) 2 (3%) 3 (5%) 1.000 
Smoking 127 (69.0%) 39 (63%) 44 (72%) 44 (72%) 0.462 
Hypertension 101 (55%) 28 (45%) 34 (56%) 39 (64%) 0.111 
Diabetes 59 (32%) 17 (28%) 18 (30%) 24 (39%) 0.332 
Culprit lesion:     0.660 
   LAD 105 (57%) 37 (60%) 38 (62%) 30 (49%)  
   LCX 20 (11%) 6 (10%) 6 (10%) 8 (13%)  
   RCA 59 (32%) 19 (31%) 17 (28%) 23 (38%)  
Killip class > Ⅰ 38 (21%) 10 (16%) 10 (16%) 18 (30%) 0.125 
TIMI risk score > 4 99 (54%) 27 (44%) 35 (57%) 37 (61%) 0.131 
CACS risk score > 1 25 (17%) 7 (11%) 11 (18%) 14 (23%) 0.226 
Medication:      
   ASA 184 (100%) 62 (100%) 61 (100%) 61 (100%) 1.000 
  P2Y12 inhibitors* 175 (95%) 60 (97%) 56 (92%) 59 (97%) 0.474 
   Beta-blocker 159 (86%) 56 (90%) 49 (80%) 54 (89%) 0.221 
   ACEI or ARB 149 (81%) 51 (82%) 50 (82%) 48 (79%) 0.892 
   Statin 170 (93%) 58 (94%) 56 (92%) 56 (93%) 0.939 
Laboratory findings:      
   Initial CPK [IU/L] 132 (85, 256) 135 (89, 259) 130 (85, 256) 129 (78, 258) 0.937 
   Peak CPK [IU/L] 1895 (769, 3757) 1594 (602, 3882) 1888 (684, 3713) 1927 (905, 3846) 0.657 
   Initial CK-MB [ng/mL] 3.3 (1.8, 10.9) 2.7 (1.7, 7.2) 3.2 (1.7, 10.9) 3.7 (1.8, 14.8) 0.661 
   Peak CK-MB [ng/mL] 184.8 (62.3, 300.0) 157.4 (60.0, 300.0) 190.5 (61.0, 300.0) 188.5 (66.7, 300.0) 0.719 
   Peak CK-MB > 300  62 (34%) 20 (32%) 21 (34%) 21 (35%) 0.942 
   Initial troponin-T [ng/mL] 0.03 (0.01, 0.13) 0.02 (0.01, 0.07) 0.02 (0.01, 0.11) 0.04 (0.01, 0.21) 0.273 
   Peak troponin-T [ng/mL] 2.74 (0.96, 6.01) 1.42 (0.44, 5.89) 3.77 (1.12, 6.75) 2.92 (0.76, 5.89) 0.117 
   Peak troponin-T > 10  23 (13%) 7 (11%) 10 (16%) 6 (10%) 0.569 
    Initial pro-BNP [pg/mL]† 90.4 (33.6, 394.8) 57.5 (24.9, 212.0) 59.9 (17.9, 335.6) 172.4 (36.8, 926.9) 0.339 
   Initial hs-CRP [mg/L] 0.16 (0.10, 0.29) 0.16 (0.10, 0.29) 0.16 (0.11, 0.41) 0.17 (0.11, 0.27) 0.728 
   Initial WBC [/uL] 11290 (8830, 13700) 11065 (8618, 
14090) 
11500 (9065, 13090) 10630 (9060, 13695) 0.825 
   Initial eosinophil [/uL] 11 (4, 20) 13 (4, 24) 10 (4, 20) 10 (3, 20) 0.524 
Major cardiac event (30 days):       
   Cardiac death 6 (3%) 2 (3%) 3 (5%) 1 (2%) 0.702 
   Heart failure 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.000 
Major cardiac event (1 year):      
   Cardiac death 6 (3%) 2 (3%) 3 (5%) 1 (2%) 0.702 
   Heart failure 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1.000 
*Ticagrelor 124 (71%), prasugrel 17 (10%), clopidogrel 39 (19%) 
†pro-BNP level was obtained in 19 subjects 
Data are presented as number (%) and mean (standard deviation) or median (interquartile). Non-parametric continuous variables, which were evaluated by the Kolmogorov-
Smimov method, were analyzed by the Kruskal Wallis test.  
sST2 — soluble suppression of tumorigenicity 2; HR — heart rate; SBP — systolic blood pressure; DBP — diastolic blood pressure; LAD — left anterior descending artery; 
LCX — left circumflex artery; RCA — right coronary artery; TIMI — Thrombolysis in Myocardial Infarction; CACS — Canada Acute Coronary Syndrome; ASA — 
acetylsalicylic acid; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin Ⅱ receptor blocker; CPK — creatine phosphokinase; CK-MB — creatine kinase 
myocardial bound; BNP — B-type natriuretic peptide; hs-CRP — high sensitivity C-reactive protein; WBC — white blood cell 
 
 
 
 
 
 
 
 
Table 2. Echocardiographic parameters according to sST2 tertile in patients with ST-elevation myocardial infarction. 
Variables 
sST2 [ng/mL] 
Tertile 1 
23.2 ≤ sST2 < 53.6  
Tertile 2 
53.6 ≤ sST2 < 72.0 
Tertile 3 
72.0 ≤ sST2 < 197.5 
P 
Baseline (n = 181)     
LVEF [%] 58 (46, 66) 62 (56, 69) 58 (52, 66) 0.241 
LVIDd [mm] 50 (47, 52) 51 (46, 54) 50 (46, 54) 0.687 
E/E’  10.3 (8.1, 12.6) 10.4 (8.5, 13.9) 11.7 (8.8, 16.2) 0.319 
LAVI [mL/m2] 27.9 (25.5, 33.3) 30.5 (26.1, 39.0) 29.7 (24.5, 36.5) 0.178 
WMSI 1.4 (1.1, 1.8) 1.4 (1.1, 1.6) 1.4 (1.1, 1.7) 0.498 
6-month follow-up (n = 103)     
LVEF (%] 63 (56, 70) 64 (58, 72) 61 (53, 69) 0.676 
LVIDd [mm] 51 (48, 54) 51 (48, 55) 51 (47, 54) 0.841 
E/E’  9.3 (7.7, 11.8) 9.9 (8.5, 14.0) 9.6 (8.4, 11.2) 0.564 
LAVI [mL/m2] 28.3 (25.3, 32.6) 31.0 (26.9, 35.7) 29.2 (24.6, 36.8) 0.459 
WMSI 1.2 (1.0, 1.6) 1.2 (1.0, 1.4) 1.3 (1.0, 1.7) 0.714 
Data are presented as number (%) and mean (standard deviation) or median (interquartile). Non-parametric continuous variables, which were evaluated by the Kolmogorov-
Smimov method, were analyzed by the Kruskal Wallis test. LVEF — left ventricular ejection fraction; LVIDd — left ventricular internal dimension, diastolic; LAVI — left 
atrial volume index; WMSI — wall motions score index 
 
 
 
 
 
 
 
 
 
Table 3. Comparisons of serial changes in echocardiographic parameters after 6 months compared to baseline. 
 ∆ 6 month – baseline P 
Tertile 1 (n = 34)   
LVEF [%] 7.3 (–0.8, 15.8) 0.001 
LVIDd [mm] 0 (–1.3, 3.5) 0.309 
E/E’  –0.7 (–2.4, 1.8) 0.487 
LAVI [mL/m2] 1.2 (–4.9, 7.1) 0.260 
WMSI –0.1 (–0.2, 0) 0.001 
Tertile 2 (n = 33)    
LVEF [%] 1.3 (–4.3, 9.1) 0.319 
LVIDd [mm] –0.5 (–3.2, 2.9) 0.894 
E/E’ 0.5 (–2.1, 2.8) 0.889 
LAVI [mL/m2] 1.2 (–5.9, 5.6) 0.407 
WMSI –0.1 (–0.2, 0.1) 0.013 
Tertile 3 (n = 36)    
LVEF [%] 1.7 (–8.1, 10.1) 0.205 
LVIDd [mm] 1.2 (–1.2, 3.8) 0.067 
E/E’ –1.0 (–2.9, 1.0) 0.090 
LAVI [mL/m2] –0.6 (–5.3, 7.8) 0.972 
WMSI 0 (–0.3, 0) 0.055 
Data are presented as median (interquartile) and were analyzed through Wilcoxon signed rank sum test. LVEF — left ventricular ejection fraction; LVIDd — left ventricular 
internal dimension, diastolic; LAVI — left atrial volume index; WMSI — wall motions score index 
 
 
 
 
 
 
 
 
Table 4. Cox regression analysis for predictors of 1-year major adverse cardiac events. 
 Univariable analysis  Multivariable model 1* 
 Unadjusted OR (95% CI) P Adjusted OR (95% CI) P 
Age 1.03 (0.96–1.11) 0.364   
Female 2.27 (0.50–14.9) 0.247   
Smoking 0.45 (0.09–2.23) 0.328   
Hypertension 4.26 (0.50–36.4) 0.186   
Diabetes 1.09 (0.20–5.92) 0.925   
Baseline SBP 0.97 (0.95–0.99) 0.001 0.97 (0.94–0.99) 0.011 
Symptom to door time 1.00 (1.00–1.00) 0.035 1.00 (1.00–1.00) 0.022 
Symptom to balloon time 1.00 (1.00–1.00) 0.036   
Door to balloon time 1.00 (0.95–1.06) 0.974   
LAD vs. non-LAD lesion 1.53 (0.28–8.34) 0.624   
Killip classification 1.61 (0.90–2.89) 0.111   
TIMI risk score 1.56 (1.12–2.16) 0.009 1.27 (0.68–2.37) 0.451 
CACS score 2.73 (1.27–5.89) 0.010 0.85 (0.16–4.36) 0.840 
Peak CPK 1.00 (1.00–1.00) 0.351   
Peak CK-MB 1.00 (0.99–1.01) 0.978   
Peak troponin-T 1.30 (1.02–1.65) 0.170   
sST2 0.99 (0.95–1.02) 0.439   
Tertile by sST2      
   Tertile 2 vs. 1 1.53 (0.26–9.12) 0.644   
   Tertile 3 vs. 1 0.51 (0.05–5.60) 0.580   
*Model 1: Adjusted for the baseline SBP, symptom to door time, TIMI risk score, and CACS score. The pro-BNP was not included in the analysis due to the small number of 
subjects. CI — confidence interval, HR — hazard ratio; OR — odds ratio; rest abbreviations are defined in Table 1 and 2. 
 Figure 1. Study flow chart of patient enrolment. 
 
Figure 2. Time-dependent changes in left ventricular ejection fraction (LVEF; A) and wall 
motions score index (WMSI; B) by sST2 tertile groups. 
 
Figure 3. Comparison of sST2 level for Killip, TIMI risk score, CACS score classification in 
patients with ST-elevation MI. (A) Killip classification 1 vs. > 1, (B) TIMI risk score <4 vs. ≥ 
4, (C) CACS score 0 vs. > 0. TIMI: thrombolysis in myocardial infarction, CACS: Canadian 
acute coronary syndrome. 
 
Figure 4. Cumulative incidence of major cardiac adverse events (MACE) during 30 days (A) 
and 1-year (B) by sST2 tertile in patients with ST-elevation myocardial infarction.  
 




